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Abstract 
Background:  Cardiac resynchronization therapy (CRT) decreases mortality, improves 
functional status and induces reverse left ventricular (LV) remodeling in selected populations 
with heart failure (HF).  The magnitude of reverse remodeling predicts survival with many HF 
medical therapies. However, there are little data assessing the impact of remodeling on long term 
survival with CRT. 
Objective:  To assess the impact of CRT induced reverse remodeling on long term survival in 
mild HF. 
Methods:  REVERSE was a multi-center, double-blind, randomized trial of CRT among patients 
with mild HF.  Long-term follow-up for 5 years was pre-planned.  The present analysis was 
confined to the 353 patients who were randomized to CRT ON with paired echocardiographic 
studies at baseline and 6 months post-implant.  Left ventricular end systolic volume index 
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(LVESVi) was measured by a core laboratory and was an independently powered endpoint of 
REVERSE. 
Results:  A 68% reduction in mortality was observed among patients with ≥15% decrease in 
LVESVi compared to the rest of the patients (p=0.0004).  Multivariable analysis showed that the 
change in LVESVi was a strong independent predictor (p=0.0002) with a 14% reduction of 
mortality for every 10% decrease of LVESVi.  Other remodeling parameters, including left 
ventricular end diastolic volume index and ejection fraction showed a similar relationship with 
mortality.   
Conclusion:  Change in left ventricular end systolic volume over 6 months of CRT is a strong 
independent predictor of long term survival in mild HF. 
Clinical Trial Registration: URL:  http://clinicaltrials.gov/ct2/show/NCT00271154.  Unique 
identifier:  NCT00271154. 
Key Words: Cardiac Resynchronization Therapy, Heart Failure, ICD, Defibrillator, Remodeling 
Abbreviations:  ACE = angiotensin converting enzyme; ARB = angiotensin receptor blockers; 
CCS = clinical composite score; CRT = cardiac resynchronization therapy; EF = ejection 
fraction; HF = heart failure; HR = hazard ratio; ICD = implantable cardioverter defibrillator; 
LBBB = left bundle branch block; LV = left ventricle; LVEDD = left ventricular end-diastolic 
dimension; LVEDVi = left ventricular end-diastolic volume index; LVESVi = left ventricular 
end-systolic volume index; NYHA = New York Heart Association. 
 
 Introduction 
Cardiac resynchronization therapy (CRT) improves functional status and cardiac function and 
decreases heart failure (HF) hospitalizations and mortality among HF patients with left 
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ventricular systolic dysfunction and QRS prolongation
1-8
.  Initially, CRT was applied to patients 
with advanced HF, but more recent studies have shown similar benefit among patients with 
milder HF
9-11
.
 
 The reverse remodeling response, as measured by left ventricular volumetric 
changes, has important prognostic significance in pharmacologic studies of HF, including 
randomized studies of angiotensin converting enzyme (ACE) inhibitors
12,13
, angiotensin receptor 
blockers (ARB)
14
,
 
beta blockers
15,16
, and with ivabradine
17
.  There are many other studies in 
support of the beneficial action of pharmacologic agents to induce reverse remodeling in HF
18
.
  
With regard to CRT, randomized trials showed that reverse remodeling predicts clinical 
outcomes and arrhythmia events
19,20
.  However, the long-term impact of remodeling on mortality 
is less well-studied.  Accordingly, the present analysis was designed to evaluate changes in left 
ventricular volume on all-cause mortality in the preplanned 5 year follow-up of the REVERSE 
Study.  
Methods 
The design and primary results of the REVERSE trial were published previously
9,21,22
.  Briefly, 
eligible patients had American College of Cardiology/American Heart Association Stage C, New 
York Heart Association (NYHA) Class I (previously symptomatic, currently asymptomatic) or 
NYHA Class II (mildly symptomatic).  Patients were required to be in sinus rhythm with QRS 
duration 120 ms, a left ventricular ejection fraction (EF) 40%, and a left ventricular end-
diastolic dimension (LVEDD) 55 mm.
,24
.  The Ethics Committee of each center approved the 
study protocol, and all patients gave written informed consent. 
      Patients were enrolled between September, 2004 and September, 2006.  All patients 
underwent implantation of a CRT system (device and leads), with or without implantable 
cardioverter defibrillator (ICD) capabilities, based on standard clinical criteria.  Patients who had 
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undergone successful implantation (n=610) were then randomly assigned in a 2:1 fashion to 
active CRT (CRT ON) or to a control group (CRT OFF).  The primary endpoint of REVERSE 
was the clinical composite score (CCS) measured at 12 months
21,25
.  Following the 
randomization period, CRT was programmed ON in all patients through 5 years post-implant to 
assess the long-term impact of this therapy.   
      Echocardiograms were obtained at baseline (prior to implant) and after 6 months of 
randomization with CRT turned off temporarily.  Data were analyzed in one of two core 
laboratories (Philadelphia, USA and Pavia, Italy) blinded to clinical data.  LV dimensions were 
recorded with 2D-directed M-mode echocardiography at the tips of the mitral valve leaflets. 
Echocardiograms were digitized to obtain LV volumes by Simpson’s method of discs, as 
recommended by the American Society of Echocardiography
26
, from which LVEF was 
calculated.  Change in LV end-systolic volume, indexed by body surface area (LVESVi), was the 
pre-defined and independently powered secondary endpoint of REVERSE.  Additional 
echocardiographic measures included LV end-diastolic volume index (LVEDVi) and EF.  
Further details of the echocardiographic protocol have been published previously
21
. 
      Patients were actively followed with in-office visits at least every 6 months through 5 years 
of follow-up, at which time patients were exited.  Mortality was assessed during this period and 
each death was adjudicated by an independent adverse events adjudication committee to classify 
the cause of death by standard criteria.  
      For the initial analysis of the effect of LVESVi change on mortality, patients were divided 
into two groups using the commonly used cutoff of a 15% decrease of volume that was 
prespecified in REVERSE
19,21
.  Subsequent analyses separated the changes into quartiles or 
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treated LVESVi change as a continuous variable to allow more detailed assessment of the 
response.   
Data Analysis 
Continuous variables are summarized with mean and standard deviation; categorical variables 
with counts and percentages.  Time to event analyses used Kaplan-Meier estimates and the log-
rank test.  Cox proportional hazards regression was used to compute hazard ratios (HR) and 
assess influence of covariates.  Time 0 in these analyses was the date of the 6-month follow-up 
visit.  Subjects were censored using the date of the latest case report form.  The covariate 
analysis of LVESVi (treated as a continuous variable) was performed using Cox proportional 
hazards methods.  A p-value <0.05 was considered statistically significant and p-values were not 
adjusted for multiple comparisons.  
 
Results 
Patient Population 
Of the 610 patients in REVERSE, 419 were randomized to CRT ON.  In this group, 66 subjects 
were not included in the present analysis for the following reasons:  six subjects died prior to 
their 6-month follow-up, 3 subjects missed their 6-month follow-up, and 57 subjects had 
inadequate echocardiograms for adequate LVESVi measurement at baseline (23), 6 months (24), 
or both (8).  Thus, there were 353 patients included in the present study.  Of note, there were no 
statistically significant differences (p<0.05) in baseline characteristics between the included and 
excluded subjects.  The 353 patients averaged 4.6 years of implanted follow-up time. 
      Baseline characteristics of the patient population are presented in Table 1.  This was a typical 
population of mild HF patients receiving CRT.  They were predominately late middle age men 
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with a majority having ischemic heart disease and an underlying left bundle branch block on the 
unpaced ECG.   
Reverse Remodeling 
The echocardiographic measures of reverse remodeling were assessed after 6 months of CRT. 
LVESVi decreased by an average of 14.9 ± 27.5 ml/m
2
, LVEDVi decreased 15.8 ± 32.4 ml/m
2
, 
and the EF increased 3.6 ± 8.3% in this cohort.  As shown previously, all of these changes were 
highly significant compared with the unpaced CRT OFF group
9
.  The pre-specified remodeling 
endpoint in this study was a reduction of LVESVi.  A reduction of at least 15% was reached by 
183 (52%) subjects.  There were some important clinical differences between subjects with a > 
15% change in LVESVi and those who did not reach this endpoint; these results are shown in 
Table 1.  Those patients with significant remodeling were more likely to be female, have non-
ischemic cardiomyopathy, and have a typical left bundle branch block (LBBB).  In addition, the 
unpaced QRS duration was longer. 
Survival with CRT 
      The REVERSE cohort was followed for 5 years as a pre-planned extension phase of the 
randomized portion of the trial
27
.  Such long-term follow-up allows for the assessment of 
mortality, which was low as expected over the first 1-2 years in patients with mild heart failure
9-
11
.  The mortality curves for the subgroups with and without significant reductions in LVESVi 
are presented in Figure 1.  The curves begin to separate about 15 months after the 6-month 
follow-up, and they continue to be separate over the full duration of follow-up.  The Hazard 
Ratio is 0.32 (p=0.0004) indicating a 68% lower mortality rate in subjects who achieved the 
remodeling endpoint (> 15% reduction in LVESVi).  It is noteworthy that the estimated long-
term mortality was very low (6.9%) in the subgroup with significant remodeling despite severe 
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systolic dysfunction and QRS prolongation at baseline.  Table 2 lists the adjudicated causes of 
death within the two groups.  The subgroup achieving the remodeling endpoint had a lower rate 
of death in all categories, including sudden and non-sudden cardiac death.   
      Although a decrease of LVESVi > 15% is commonly used to define an echocardiographic 
remodeling response to CRT, this arbitrary cutoff could affect the results.  Therefore, the 
response was subdivided in quartiles to evaluate the effect on remodeling more accurately.  The 
largest remodeling response (quartile 4) was a > 32.1% reduction of LVESVi, whereas patients 
with an increase of LVESVi despite CRT constituted quartile 1.  These results are shown in 
Figure 2.  There was again a very significant effect of change of LVESVi on mortality 
(p<0.0001) with the lowest mortality among subjects with the largest reduction and a very high 
mortality among subjects with an increase in LV volume at 6 months.   
     Current guidelines strongly recommend CRT in mild heart failure only for patients with 
LBBB
28
\; accordingly, the analysis was repeated in subgroups based on QRS morphology.  
These results are presented separately in Figure 3 for the LBBB (n=217) and non-LBBB (n=133) 
cohorts.  The p-values within both groups were significant indicating that change in LVESVi is a 
significant factor in predicting future mortality in both LBBB and non-LBBB patients. 
      As noted previously, there were some important clinical differences between the subjects in 
the different remodeling subgroups, so a multi-variable analysis was performed.  For this 
analysis, the change in LVESVi was treated as a continuous variable.  These results are shown in 
Table 3.  After adjusting for important covariates, remodeling was a strong independent predictor 
(p=0.0002) with a 14% reduction of mortality for every 10% decrease of LVESVi.  The other 
significant predictors of mortality were baseline LVESVi, QRS duration, device type (CRT-D or 
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CRT-P), and sex with better survival in subjects with smaller left ventricular volume, longer 
QRS duration, CRT-D recipients, and women.  
      Analyses were also performed with other remodeling parameters.  The results for LVEDVi 
are shown in Panel A of Figure 4 and they are strikingly similar to the results for LVESVi.  The 
survival curves grouped by changes in LVEF are shown in Panel B.  Again, there is a strong 
relationship between the magnitude of change of EF and long-term mortality with CRT. 
 
Discussion 
The primary result of the present analysis is that the change in LVESVi with CRT was a strong 
independent predictor of long-term mortality in mild HF.  Specifically, among subjects with a > 
15% reduction of LVESVi after 6-months of CRT, all-cause mortality was 1.6% annually.  This 
was a 68% lower mortality relative with the rest of the cohort.  A more detailed analysis of 
response identified a very high risk cohort with further LV dilation with CRT, which constituted 
about 25% of the population.  Mortality was more than 4-fold greater in this subgroup (29.8% vs 
6.9% for > 15% reduction of LVESVi).  Finally, the magnitude of other echocardiographic 
measures of remodeling (LVEDVi and EF) also showed strong relationships with long term 
survival.   
      The impact of LV volumetric changes on mortality has been assessed previously in both 
pharmacologic and CRT studies.  In SOLVD Treatment, subjects receiving enalapril had a mean 
12.3% reduction in LVESVi.  Correspondingly, those patients in the active drug arm had a 16% 
relative risk reduction in mortality
19,29
.  Other studies of ACE inhibitors or ARBs have 
consistently shown the important prognostic value of echocardiographic volumetric changes on 
long term outcomes and survival
14,18
.  Studies of carvedilol have also shown an association 
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between reverse remodeling and reduced mortality
15,16
.
 
 Similar findings were shown with 
ivabradine therapy among patients already on betablocker therapy
17
.  Interestingly, an increase in 
mortality has been observed in pharmacologic treatment that increases LV volumes.  This was 
shown in the ibopamine trial
25
.  These findings are supported further by a recent meta-analysis 
comprising 30 mortality studies, 25 drug/device therapies and 88 remodeling trials of these 
therapies in HF patients.  Short term LV remodeling was associated with lower mortality
18 
with 
more pronounced mortality effects among patients with greater reductions in LV volumes. 
      CRT and betablockers are linked to the greatest magnitude of left ventricular reverse 
remodeling compared to other heart failure drug therapies
18
.
  
More than 95% of patients in more
 
recent randomized clinical trials of CRT have been on betablockers
10-12
.  Reverse remodeling by 
beta blockade is dependent on dose
15
.  In REVERSE, 60% were on at least 50% of guideline-
indicated dose and 30% on target dose
31
.  As CRT can be used as further therapy in addition to 
beta blockade, this combination may be the most potent in terms of reverse remodeling which is 
reflected in our results.  To our knowledge, REVERSE is the first study to show that reverse 
remodeling by a non-pharmacological HF therapy is an independent predictor of long term 
survival. 
     With regard to previous studies of CRT, several studies demonstrated a relationship between 
remodeling and composite endpoints including survival.  Ypenburg et al
26
 reported a relationship 
between the extent of LV volume changes and mortality and heart failure hospitalizations.  
Similarly, Yu et al
27
 showed that a reduction in LVESV of 10% significantly lowers the risk of 
mortality and heart failure events.  Finally, analysis of the MADIT CRT study showed a 
reduction of the composite endpoint of HF hospitalization and survival in both the CRT and ICD 
groups
29
.
  
The present results suggest that large reductions of LVESVi are associated with 
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decreases of both non-sudden and sudden death.  The impact of reverse remodeling on HF 
mortality is not surprising given the associations of remodeling with reductions of HF 
hospitalization noted above.  LV volumetric changes have also been shown to decrease 
ventricular arrhythmia in both the REVERSE
19
 and MADIT CRT
35
 studies, so again it follows 
that a reduction of sudden death may be expected long term. There was also an apparent decrease 
in non-cardiac death.  Whether this was due to the identification of a sicker subgroup of patients 
more prone to die from the sequela of HF, such as renal failure or infection, or to mortality 
classification difficulties cannot be determined from these results. 
      The impact of reverse remodeling on long term mortality was noted for the non-LBBB 
subgroups.  This is particularly interesting, as current guidelines do not recommend CRT for 
these patients with mild HF on the results of large randomized trials
10,11
.  The remodeling 
response is much smaller in non-LBBB subjects
36-38
, which is consistent with poorer outcomes.  
However, the present results indicate improved survival in those subjects who have a significant 
decrease in LVESVi with CRT.  Further study is needed to assess if there are predictors of a 
good remodeling response in the non-LBBB cohort who may benefit from CRT. 
      There are several clinical implications of these data.  First, the present findings confirm that 
echocardiographic measures of remodeling are an important endpoint for CRT response.  Such 
responses at 6 months are a strong predictor of mortality, so this should be considered as an 
endpoint for studies designed to optimize CRT, as it would save considerable sample size and 
time over studies using mortality as an endpoint.  Second is the observation that further LV 
dilation despite CRT is a very poor prognostic sign with a high mortality.  These patients should 
be considered for intervention including alternative advanced heart failure therapy optimization 
of programming parameters, lead repositioning or even discontinuation of CRT.  Finally, the 
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clinical predictors of long term mortality with CRT are very similar to the predictors of clinical 
response in mild HF
9-11,35-37
.  Specifically, in addition to the change of LVESVi, women, 
increased unpaced QRS duration, CRT-D devices, and smaller LV volumes were associated with 
lower mortality.  CRT-D had been previously shown to be associated with reduced mortality
39
, 
while the other factors were shown to be associated with reduced HF hospitalizations
9-11
.  
      This study should be interpreted in the face of several methodological limitations.  The 
REVERSE study was double-blinded only during the randomized phase including the 
echocardiographic assessment.  It is conceivable that this affected treatment at different phases of 
the study.  In addition, titration of medications was discouraged during the randomized phase and 
this may affect long-term outcome.  Finally, this study only evaluated subjects with mild HF.  
 
Conclusions 
In summary, in the long-term follow-up of REVERSE patients with CRT, reverse remodeling, as 
defined as a > 15% reduction of LVESVi was associated with a 68% mortality reduction.  
Analysis adjusting for baseline covariates showed a 14% reduction in mortality for every 10% 
change in LVESVi.  Finally, the subgroup of patients who continue to remodel despite CRT 
(LVESVi increases) have a markedly increased mortality. 
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Clinical Perspective 
Pharmacologic therapies for systolic heart failure (HF) that are associated with reverse left 
ventricular remodeling produce a mortality benefit. In the present study, the long term effect of 
reverse remodeling on mortality with cardiac resynchronization therapy (CRT) was assessed. A 
15% or greater reduction of LVESVi, which is the standard measure of remodeling with CRT, 
was associated with a 68% all-cause mortality reduction. Similar results were observed with 
other remodeling parameters, including a reduction of LVEDVi or an increase of ejection 
fraction. Equally important, the subgroup of patients who continue to remodel despite CRT have 
a markedly increased mortality. These findings indicate that reverse remodeling should be a goal 
of CRT therapy and is an appropriate short term (6 months) endpoint for interventions to 
optimize this treatment.  Such interventions include physiologic measures to optimize LV lead 
position or programmed pacing parameters. However, continued LV dilation with CRT is a 
marker of a poor prognosis and warrants aggressive treatment, such as alternative HF therapies 
or considering inhibiting CRT.  
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Tables 
Table 1.  Baseline Patient Characteristics  
 
LVESVi Change at 6 
Months 
 
 
 
Increased or 
decreased 
<15% 
(n=170) 
Decreased  
≥15% 
(n=183) 
All Patients 
(n=353) p-value 
Age, mean (yrs) 63.8 ± 9.4 62.2 ± 11.5 63.0 ± 10.6 0.15 
Male (%)  87.1 66.7 76.5 <0.0001 
Ischemic etiology (%)  68.8 45.4 56.7 <0.0001 
CRT-D (%) 88.8 76.0 82.2 0.002 
NYHA II (%)  79.4 83.1 81.3 0.41 
LBBB 
RBBB 
IVCD  
47.3 
14.2 
38.5 
75.7 
3.3 
21.0 
62.0 
8.6 
29.4 
<0.0001 
LVEF (%)  26.4 ± 7.3 27.2 ± 6.7 26.8 ± 7.0 0.26 
LVESVi (ml/m
2
) 97.9 ± 35.7 100.8 ± 33.9 99.4 ± 34.7 0.42 
QRS (ms)  148 ± 20 157 ± 21 153 ± 20 <0.0001 
Diabetes (%) 25.9 18.0 21.8 0.09 
ACE Inhibitor or ARB 
(%)  
95.9 96.7 
96.3 
0.78 
Beta-blocker (%)  94.1 95.6 94.9 0.63 
Diuretics (%) 80.6 78.7 79.6 0.69 
Continuous variables are represented by mean ± standard deviation.  Student’s t-test or Fisher’s exact test are used to test for statistical 
significance between groups in the first 2 columns.  ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CRT-D, 
cardiac resynchronization therapy with implantable defibrillators; CRT-P, CRTpacemakers; LBBB, left bundle–branch block; LVEF, left 
ventricular ejection fraction; LVESVi, left ventricular end systolic volume index; NYHA, New York Heart Association; and RBBB, right 
bundle–branch block. 
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Table 2.  Causes of Death 
 
 
 Increased or 
decreased 
<15% 
(n=170) 
Decreased  
≥15% 
(n=183) 
Cardiac 
Sudden  6 (3.5%) 1 (0.5%) 
Non-
sudden  
Heart failure 9 (5.3%) 5 (2.7%) 
Non-HF 0 (0.0%) 1 (0.5%) 
Non-cardiac   16 (9.4%) 5 (2.7%) 
Unknown   2 (1.2%) 0 (0.0%) 
Total   33 (19.4%) 12 (6.6%) 
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Table 3 Multi-variable Analysis of Mortality >6 Months after CRT 
Parameter Comparison 
Hazard 
Ratio 95% CI P-value 
% Change in LVESVi 
over 6 Months 
Per 10% 0.86 0.79-0.93 0.0002 
Age Per 10 years 1.33 0.94-1.87 0.11 
Sex Female vs Male 0.09 0.01-0.65 0.02 
Ischemic 
Ischemic vs Non-
ischemic 
1.53 0.65-3.60 0.33 
Baseline LVESVi Per 10 ml/m
2
 1.16 1.07-1.26 0.0003 
Baseline QRS 
Duration 
Per 10 ms 0.83 0.70-0.99 0.04 
LBBB 
LBBB vs Non-
LBBB 
0.56 0.28-1.15 0.11 
Baseline NYHA Class I vs Class II 0.71 0.32-1.54 0.38 
Diabetic Yes vs No 0.86 0.42-1.76 0.68 
Device Type CRT-P vs. CRT-D 2.74 1.29-5.81 0.009 
  
24 
 
Figure Legends 
 
Figure 1. Kaplan-Meier curves of mortality for the subgroup with changes in LVESVI > 15% 
after 6 months of CRT and the rest of the cohort. 
Figure 2. Kaplan-Meier curves of mortality for quartiles based on percentage changes in 
LVESVi  after 6 months of CRT. 
Figure 3. Kaplan-Meier curves of mortality for quartiles based on percentage changes in 
LVESVi  after 6 months of CRT, examining LBBB and non-LBBB subgroups. 
Figure 4. Kaplan-Meier curves of mortality for quartiles based on reverse remodeling changes 
after 6 months of CRT. Panel A: LVEDVi. Panel B; LVEF 
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Fig 3 
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